Can-Fite BioPharma (CANF) announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small ...

After establishing itself as one of the top rushing defenses last season, the Arizona State defensive line unit has a new ...

Arizona State football defensive lineman C.J. Fite explains what makes this Sun Devil defensive line group what it is.

Alliance Global Partners analyst James Molloy lowered the firm’s price target on Can-Fite BioPharma (CANF) to $4.50 from $12 and keeps a Buy ...

John Richard “Johnny” Fite, 72, went home to be with the Lord on April 15, 2025, at his home in Fairview. In heaven he was reunited with his loving mother, Elizabeth Mary Williams Fite ...

Liver Cancer - A patient, who initially had an overall survival time of 8 years, currently treated with Namodenoson in a compassionate use program in the former Can-Fite Phase II study has ...

Can-Fite BioPharma Ltd. has announced the completion of a Phase II study design and is preparing to initiate a clinical study for Piclidenoson, a novel treatment for Lowe Syndrome, a rare genetic ...

Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...

Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 ...